Glycomine
Mannose-1 phosphate substrate replacement therapy for PMM2-CDG
- Sector
- Biotech
- Headquarters
- SAN FRANCISCO, CA
- Founded
- 2014
- Latest Form D
- $4.9M, Nov 2016
- Total capital
- $4.9M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $4.9M
- 1 Form D · last Nov 2016
- 120 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 18 pending · first 2019
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$4.9M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Agnes RafalkoResearcherExecutive Officer, DirectorLinked by 2 patents
- Christopher C.M. StarrDirectorNamed in SEC Form D filings
- Giacomo C.M. ChiesiDirectorNamed in SEC Form D filings
- Peter C.M. McWilliamsDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 20- PendingContinuous Flow Methods For Producing MANNOSE-1-PHOSPHATE, Polymorphs Of MANNOSE-1-PHOSPHATE, And Compositions And Uses Related TheretoUSPTOApplication 18866947
- PendingPharmaceutical Preparation Of Carbohydrates For Therapeutic UseUSPTOApplication 18777142
- PendingPharmaceutical Preparation Of Carbohydrates For Therapeutic UseUSPTOApplication 18193328
Show all 20 patent records
- Continuous Flow Methods For Producing MANNOSE-1-PHOSPHATE, Polymorphs Of MANNOSE-1-PHOSPHATE, And Compositions And Uses Related TheretoJan 15, 2026 · Application 18866947Pending
- Pharmaceutical Preparation Of Carbohydrates For Therapeutic UseJun 12, 2025 · Application 18777142Pending
- Pharmaceutical Preparation Of Carbohydrates For Therapeutic UseMar 14, 2024 · Application 18193328Pending
- Liposomal Formulations, And Methods Of Using And Preparing ThereofJun 16, 2022 · Application 17593755Pending
- Pharmaceutical Preparation Of Carbohydrates For Therapeutic UseApr 14, 2022 · Application 17327241Pending
- Pharmaceutical Preparation Of Carbohydrates For Therapeutic UseJun 29, 2021 · US 11,045,419Granted
- Pharmaceutical Preparation Of Carbohydrates For Therapeutic UseOct 22, 2019 · US 10,449,149Granted
- Pharmaceutical Preparation Of Carbohydrates For Therapeutic UseAug 11, 2016 · Application 15022194Pending
- Liposomal Formulations For Treating Hyperinsulinemic Hypoglycemia Or Polycystic Kidney Diseases, And Their Co-occurrenceApplication 63000862Pending
- Liposomal Formulations, And Methods Of Using And Preparing ThereofApplication 62826874Pending
- Pharmaceutical Preparation Of Carbohydrates For Therapeutic UseApplication PCTUS2014055921Pending
- Methods Of Treating Congenital Disorders Of Glycosylation (cdg) And Ataxia In Subjects Suffering From CdgApplication PCTUS2025017678Pending
- Pharmaceutical preparation of carbohydrates and glycolipids for therapeutic useApplication 61878591Pending
- Liposomal Formulations, And Methods Of Using And Preparing ThereofApplication PCTUS2025017681Pending
- Methods Of Treating Congenital Disorders Of GlycosylationApplication 63559858Pending
- Methods Of Treating Ataxia In Humans Suffering From PMM2-CDGApplication 63559845Pending
- Liposomal Formulations, And Methods Of Using And Preparing ThereofApplication 63559841Pending
- Continuous Flow Methods For Producing MANNOSE-1-PHOSPHATE, Polymorphs Of MANNOSE-1-PHOSPHATE, And Compositions And Uses Related TheretoApplication PCTUS2023022561Pending
- Continuous Flow Methods For Producing MANNOSE-1-PHOSPHATE, Polymorphs Of MANNOSE-1-PHOSPHATE, And Compositions And Uses Related TheretoApplication 63343447Pending
- Liposomal Formulations, And Methods Of Using And Preparing ThereofApplication PCTUS2020025246Pending
Related companies, and why
- EXAVIR THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
- Go Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- OPAL THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- Glyscend IncSimilar federal contract value in Biotech · null in contracts
- Spectrum Antimicrobials, Inc.Similar federal contract value in Biotech · null in contracts
- Lipidio Pharmaceuticals Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .